Biomarkers in Nephropathic Cystinosis: Current and Future Perspectives

Cells. 2022 Jun 4;11(11):1839. doi: 10.3390/cells11111839.


Early diagnosis and effective therapy are essential for improving the overall prognosis and quality of life of patients with nephropathic cystinosis. The severity of kidney dysfunction and the multi-organ involvement as a consequence of the increased intracellular concentration of cystine highlight the necessity of accurate monitoring of intracellular cystine to guarantee effective treatment of the disease. Cystine depletion is the only available treatment, which should begin immediately after diagnosis, and not discontinued, to significantly slow progression of renal and extra-renal organ damage. This review aims to discuss the importance of the close monitoring of intracellular cystine concentration to optimize cystine depletion therapy. In addition, the role of new biomarkers in the management of the disease, from timely diagnosis to implementing treatment during follow-up, is overviewed.

Keywords: biomarkers; cysteamine; cystine; kidney; nephropathic cystinosis; therapeutic monitoring.

Publication types

  • Review

MeSH terms

  • Biomarkers
  • Cysteamine
  • Cystine
  • Cystinosis* / diagnosis
  • Fanconi Syndrome*
  • Humans
  • Quality of Life


  • Biomarkers
  • Cystine
  • Cysteamine

Grant support

This research received no external funding.